Patient 2
A woman in her 70s with a history of venous insufficiency, rheumatoid arthritis, osteoporosis, and β-thalassemia presented with a 3-month history of ulceration on the dorsum of her right foot ( Figure 1) . Her wound was diagnosed as an atypical venous ulcer, given its unusual location, and initially treated with multilayered elastic compression bandages (Profore), which were changed weekly, and foam dressings (Allevyn). Her target ulcer did not close completely with standard of care or adjuvant bilayered living skin equivalent (Apligraf). Her wound was 1.0 cm 2 when topical timolol, 0.5% (Timoptic), was instilled, 1 drop every 2 cm of wound edge weekly, then covered with silicone foam and a 4-layer compression bandage. Her target ulcer reepithelialized after 7 weeks of treatment ( Figure 2 ).
Patients 3 Through 5
Three additional wounds were treated with topical timolol, 0.5% (Timoptic). The clinical findings of these patients are given in the Table. Therapeutic Challenge Chronic, recalcitrant wounds fail to progress through the normal stages of wound healing. The most common cause of chronic wounds or ulcers include venous or arterial insuf-ficiency, repetitive trauma from neuropathy, or prolonged pressure. 1 Management of chronic wounds can be costly and time-consuming, necessitating selectivity of available treatment modalities to optimize care. Differential effects on keratinocyte migration and differentiation have been seen with a number of molecules, including growth factors and corticosteroids. Recent in vitro and in vivo animal research suggests catecholamines and β-adrenergic receptors may be new targets to augment the wound healing process. [2] [3] [4] Solution to the Problem A commercially available B2AR antagonist (timolol), typically used as an intraocular glaucoma medication, was instilled in different chronic, recalcitrant wounds of 5 patients. Each patient experienced limited healing success with other modalities, including standard of care and adjuvant therapies, before switching to topical timolol. No patients included in this case series received systemic β-adrenergic antagonists at time of treatment. Patients were treated with 
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Case Report/Case Series | THE CUTTING EDGE topical timolol on either a daily or weekly basis, dependent on frequency of dressing changes for each specific wound, combined with standard of care. Optimal dosing is not yet known. Medication was instilled with 1 drop every 2 cm along the wound edge and allowed to dry for 2 minutes without further manipulation. Wounds were covered with foam dressings to provide fluid absorption; however, occlusive dressing selection should be determined by the treating physician. Patients received treatments for 4 to 8 weeks. Each patient improved with topical timolol, 0.5%, including 3 patients who had complete healing. The mean reduction of wound size after 7 weeks of treatment was 78.2%.
Discussion
β-Adrenergic receptors are present on cells in multiple organ systems, including the skin. Within skin, receptors are present on keratinocytes, fibroblasts, and melanocytes, and they may have a role in the pathophysiology of dermatologic conditions, including atopic eczema, psoriasis, and vitiligo. 5 In acute partial-thickness donor site wounds, B2AR antagonists have been reported to promote wound healing, and one potential mechanism of action is via keratinocyte migration.
Keratinocyte migration occurs by the facilitation of chemotaxis, the polarization of cells, and activation of extracellular signal-related kinases essential in the signaling of promigratory pathways. The B2AR activation inhibits keratinocyte migration by activating the serine/threonine phosphatase 2A, which downregulates phosphorylation of extracellular signal-related kinases necessary for migration. 2 Therefore, B2AR antagonists prevent the phosphorylation of phosphatase 2A and have the downstream effect of extracellular signal-related kinase promotion, inducing a promigratory pathway in keratinocytes.
Keratinocyte migration also occurs by galvanotaxis, a phenomenon in which cells migrate in response to electric stimuli. Keratinocytes can be stimulated to migrate with the formation of electrical poles and the application of electrical fields. 2 The B2AR antagonists improve the ability of keratinocytes to respond to such migratory cues, whereas the B2AR agonists decrease keratinocytes' ability to respond, further implicating the use of topical timolol for recalcitrant wounds. 3 In the setting of burn wounds, high-stress environments exist with elevated catecholamine levels, both systemically and locally. 4, 6 A study 4 that evaluated wounded keratinocytes in an ex vivo model demonstrated inc reased catecholamine-producing enzymes, tyrosine hydroxylase, and phenylethanolamine-N-methyltransferase. In a doubleblinded randomized controlled trial, patients who received oral propranolol had a shorter time to healing of superficial wounds, were quicker to receive skin grafts in deeper injuries, and had shorter hospital stays compared with the placebo group. 7 Previous data have indicated that B2AR antagonists may impair cellular immunity and insulin sensitivity. 8, 9 However, the active drug groups did not have increased incidences of sepsis or mortality.
Angiogenesis and dermal fibroblast proliferation are also regulated by B2ARs. The B2AR antagonists have been found to promote angiogenesis in chick chorioallantoic membrane assays and in vivo murine wound models. Dermal fibroblast migration is also increased (by 27%) when exposed to B2AR antagonists, and epidermal differentiation is improved with B2AR antagonists and β 1 -and β 2 -receptor antagonists. 10 It is not yet clear whether catecholamines are produced endogenously by wounded keratinocytes. If keratinocytes 
